{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:47:22Z","timestamp":1792165642891,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"am","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jbspin.2019.01.018","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T21:36:45Z","timestamp":1549402605000},"page":"37-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Statins, myalgia, and rhabdomyolysis"],"prefix":"10.1016","volume":"87","author":[{"given":"Anne","family":"Tournadre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2019.01.018_bib0005","first-page":"378","article-title":"Cholest\u00e9rol LDL moyen et pr\u00e9valence de l\u2019hypercholest\u00e9rol\u00e9mie LDL chez les adultes de 18 \u00e0 74 ans, \u00e9tude nationale nutrition sant\u00e9 (ENNS) 2006-2007, France m\u00e9tropolitaine","volume":"31","author":"De Peretti","year":"2013","journal-title":"BEH"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0010","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - Principales dyslipid\u00e9mies : strat\u00e9gies de prise en charge- F\u00e9vrier 2017 [Internet]. [cited 2018 Aug 3]. Available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2039802\/fr\/principales-dyslipidemies-strategies-de-prise-en-charge."},{"key":"10.1016\/j.jbspin.2019.01.018_bib0015","unstructured":"Usage des Statines-Assurance maladie-29 mai 2013 [Internet]. Available from: https:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/29052013_DP_Usage_statines_mai_2013_vdef.pdf."},{"key":"10.1016\/j.jbspin.2019.01.018_bib0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"217","author":"Catapano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0030","first-page":"203","article-title":"Causal effect of lipids and lipoproteins on atherosclerosis: lessons from genomic studies","volume":"36","author":"Ference","year":"2018","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0040","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0045","first-page":"296","article-title":"Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up","volume":"35","author":"Tournadre","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0050","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0055","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0060","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.amjcard.2014.02.033","article-title":"Statin intolerance","volume":"113","author":"Ahmad","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0070","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0080","article-title":"Statins for primary prevention and rhabdomyolysis: a nationwide cohort study in France","author":"Coste","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0085","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0090","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/HCO.0000000000000317","article-title":"An update on the relationship between statins and physical activity","volume":"31","author":"Panza","year":"2016","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0095","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00131402-200103000-00003","article-title":"HMG-CoA reductase inhibitor myopathy: Clinical, electrophysiological, and pathologic data in five patients","volume":"2","author":"Meriggioli","year":"2001","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0115","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0125","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1186\/ar4468","article-title":"Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies","volume":"16","author":"Drouot","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0130","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"Immune-mediated necrotizing myopathies working group. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0145","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0150","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies: Anti-SRP and Anti-HMGCR","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jbspin.2013.06.008","article-title":"Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins","volume":"81","author":"Lahaye","year":"2014","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0165","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0170","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0175","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0180","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.revmed.2017.10.426","article-title":"Should statin therapy be discontinued in the elderly?","volume":"39","author":"Bonnet","year":"2018","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jbspin.2019.01.018_bib0190","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Echaniz-Laguna","year":"2010","journal-title":"N Engl J Med"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X19300168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:25:14Z","timestamp":1761150314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X19300168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1297319X19300168"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.018","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins, myalgia, and rhabdomyolysis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2019.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}